<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02457338</url>
  </required_header>
  <id_info>
    <org_study_id>631099</org_study_id>
    <nct_id>NCT02457338</nct_id>
  </id_info>
  <brief_title>Infant Microbiota and Probiotic Intake Study</brief_title>
  <acronym>IMPRINT</acronym>
  <official_title>Infant Supplementation With Probiotic Bifidobacterium Longum Subsp. Infantis Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Evolve BioSystems, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if supplementing healthy term infants delivered by
      C-section or vaginal delivery who only consume breastmilk with a probiotic for 21 consecutive
      days increases levels of bacteria in infants' stool.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this clinical trial is to determine the effects of supplementing the probiotic
      Bifidobacterium longum subsp. infantis for the first 21 days of life in healthy term
      breastfed infants delivered via C-section or vaginal delivery on gut bacteria composition
      during, 1 week, and 1 month after supplementation compared with matched-control term infants
      receiving standard care. The investigators' specific aim is to compare the fecal microbiota
      (total B. infantis, total Bifidobacterium, total bacteria and composition of microbiota)
      between the supplement and control groups.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">June 2027</completion_date>
  <primary_completion_date type="Anticipated">June 2027</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Infant fecal B. infantis</measure>
    <time_frame>baseline, days 10, 14, 17, 21, 25, 29, 32, 40, 50, 60</time_frame>
    <description>Measure the change from baseline, during supplementation, and post supplementation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infant fecal Bifidobacterium</measure>
    <time_frame>baseline, days 10, 14, 17, 21, 25, 29, 32, 40, 50, 60</time_frame>
    <description>Measure the change from baseline, during supplementation, and post supplementation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infant fecal total bacteria</measure>
    <time_frame>baseline, days 10, 14, 17, 21, 25, 29, 32, 40, 50, 60</time_frame>
    <description>Measure the change from baseline, during supplementation, and post supplementation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infant fecal microbiota</measure>
    <time_frame>baseline, days 10, 14, 17, 21, 25, 29, 32, 40, 50, 60</time_frame>
    <description>Measure the change from baseline, during supplementation, and post supplementation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Adverse Events and Treatments</measure>
    <time_frame>Baseline-days 60</time_frame>
    <description>Gastrointestinal symptoms and related symptoms (discomfort passing bowel movements, vomiting, constipation, colic or irritability) before, during and after B. infantis supplementation will be determined and reported daily by parental self-report questionnaire. General health status of the infant such as occurrence of any illness, health care visits for sickness, fever, antibiotic and medication use and parental assessments of infant's overall health.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Infant fecal bacteria oligosaccharide consumption</measure>
    <time_frame>days 7, 14, 21, 32, 60</time_frame>
    <description>Compare the oligosaccharides in human milk against the oligosaccharides in infant feces before, during, and after B. infantis supplementation by using liquid chromatography Chip-TOP mass spectrometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infant fecal sialic acid concentrations</measure>
    <time_frame>baseline, days 10, 14, 17, 21, 25, 29, 32, 40, 50, 60</time_frame>
    <description>Measure the change in infant fecal sialic acid concentrations before, during, and after B. infantis supplementation in infant stool samples using enzymatic assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal fecal B. infantis, Bifidobacterium, total bacteria, and microbiota composition</measure>
    <time_frame>baseline, day 60</time_frame>
    <description>Compare the maternal fecal B. infantis, bifidobacterium, total bacteria, and microbiota composition with changes in infant fecal microbiota</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infant weight</measure>
    <time_frame>birth, hospital discharge, days 15, 33, 61</time_frame>
    <description>Determine the change in weight across the study duration using a digital infant scale and change in gut microbiota</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fecal inflammatory mediators</measure>
    <time_frame>Baseline-days 60</time_frame>
    <description>Compare GI function between infants in the B. infantis and control groups through the measurement of fecal inflammatory mediators.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fecal gut barrier function barrier markers</measure>
    <time_frame>Baseline-days 60</time_frame>
    <description>Compare GI function between infants in the B. infantis and control groups through the measurement of GI barrier function markers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fecal lipopolysaccharide</measure>
    <time_frame>Baseline-days 60</time_frame>
    <description>Compare GI function between infants in the B. infantis and control groups through the measurement of fecal lipolysaccharide binding.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fecal short-chain fatty acids</measure>
    <time_frame>Baseline-days 60</time_frame>
    <description>Determine the relationship between fecal microbiota composition and fecal short chain fatty acids</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Supplement Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group will receive probiotic B. infantis supplementation, plus standard care and lactation consultation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This group will receive standard care plus lactation consultation only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Bifidobacterium</intervention_name>
    <arm_group_label>Supplement Group</arm_group_label>
    <other_name>B. infantis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy, non-smoking women and their infants

          -  Who are pregnant in their third trimester OR have delivered by C-section or vaginal
             birth within the past 7 days

          -  Patients who live within a 20-mile radius from UCDMC or a 20-mile radius from UC Davis
             Campus in Davis, CA

          -  Plan to exclusively breastfeed their infants for at least 3 months

          -  Infants: 0-7 days old, delivered by C-section or vaginal delivery, born &gt;37 weeks
             gestation, without medical complications that would preclude breastfeeding or alter
             gut microbiota

        Exclusion Criteria:

          -  Infants born with medical complications such as: respiratory distress syndrome, birth
             defects, and infection

          -  Infants who have taken antibiotics for more than 72 hours of life

          -  Infants who have consume formula feedings after day 7 of life

          -  Mothers and their infants who are not discharged from the hospital by day 4 of life
             due to complications

          -  Plan to administer probiotics to infants or use of probiotics other than the study
             supplement by infants anytime throughout the study duration

          -  Women who have had any breast surgery or injury within the past 5 years that would
             reduce the chance of successful exclusive breastfeeding

          -  Mothers who have a chronic metabolic disease or obesity
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer Smilowitz, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Underwood, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://ffhi.ucdavis.edu/human-studies/infant-microbiota-and-probiotic-intake-imprint-study</url>
    <description>University of California, Davis Foods for Health Institute</description>
  </link>
  <reference>
    <citation>Prior E, Santhakumaran S, Gale C, Philipps LH, Modi N, Hyde MJ. Breastfeeding after cesarean delivery: a systematic review and meta-analysis of world literature. Am J Clin Nutr. 2012 May;95(5):1113-35. doi: 10.3945/ajcn.111.030254. Epub 2012 Mar 28. Review.</citation>
    <PMID>22456657</PMID>
  </reference>
  <reference>
    <citation>Bager P, Wohlfahrt J, Westergaard T. Caesarean delivery and risk of atopy and allergic disease: meta-analyses. Clin Exp Allergy. 2008 Apr;38(4):634-42. doi: 10.1111/j.1365-2222.2008.02939.x. Epub 2008 Feb 11.</citation>
    <PMID>18266879</PMID>
  </reference>
  <reference>
    <citation>Pei Z, Heinrich J, Fuertes E, Flexeder C, Hoffmann B, Lehmann I, Schaaf B, von Berg A, Koletzko S; Influences of Lifestyle-Related Factors on the Immune System and the Development of Allergies in Childhood plus Air Pollution and Genetics (LISAplus) Study Group. Cesarean delivery and risk of childhood obesity. J Pediatr. 2014 May;164(5):1068-1073.e2. doi: 10.1016/j.jpeds.2013.12.044. Epub 2014 Feb 5.</citation>
    <PMID>24508442</PMID>
  </reference>
  <reference>
    <citation>Bager P, Simonsen J, Nielsen NM, Frisch M. Cesarean section and offspring's risk of inflammatory bowel disease: a national cohort study. Inflamm Bowel Dis. 2012 May;18(5):857-62. doi: 10.1002/ibd.21805. Epub 2011 Jul 7.</citation>
    <PMID>21739532</PMID>
  </reference>
  <reference>
    <citation>Garrido D, Barile D, Mills DA. A molecular basis for bifidobacterial enrichment in the infant gastrointestinal tract. Adv Nutr. 2012 May 1;3(3):415S-21S. doi: 10.3945/an.111.001586. Review.</citation>
    <PMID>22585920</PMID>
  </reference>
  <reference>
    <citation>Garrido D, Dallas DC, Mills DA. Consumption of human milk glycoconjugates by infant-associated bifidobacteria: mechanisms and implications. Microbiology. 2013 Apr;159(Pt 4):649-64. doi: 10.1099/mic.0.064113-0. Epub 2013 Mar 4. Review.</citation>
    <PMID>23460033</PMID>
  </reference>
  <reference>
    <citation>Garrido D, Kim JH, German JB, Raybould HE, Mills DA. Oligosaccharide binding proteins from Bifidobacterium longum subsp. infantis reveal a preference for host glycans. PLoS One. 2011 Mar 15;6(3):e17315. doi: 10.1371/journal.pone.0017315.</citation>
    <PMID>21423604</PMID>
  </reference>
  <reference>
    <citation>Garrido D, Nwosu C, Ruiz-Moyano S, Aldredge D, German JB, Lebrilla CB, Mills DA. Endo-β-N-acetylglucosaminidases from infant gut-associated bifidobacteria release complex N-glycans from human milk glycoproteins. Mol Cell Proteomics. 2012 Sep;11(9):775-85. doi: 10.1074/mcp.M112.018119. Epub 2012 Jun 27.</citation>
    <PMID>22745059</PMID>
  </reference>
  <reference>
    <citation>Garrido D, Ruiz-Moyano S, Jimenez-Espinoza R, Eom HJ, Block DE, Mills DA. Utilization of galactooligosaccharides by Bifidobacterium longum subsp. infantis isolates. Food Microbiol. 2013 Apr;33(2):262-70. doi: 10.1016/j.fm.2012.10.003. Epub 2012 Oct 22.</citation>
    <PMID>23200660</PMID>
  </reference>
  <reference>
    <citation>Ruiz-Moyano S, Totten SM, Garrido DA, Smilowitz JT, German JB, Lebrilla CB, Mills DA. Variation in consumption of human milk oligosaccharides by infant gut-associated strains of Bifidobacterium breve. Appl Environ Microbiol. 2013 Oct;79(19):6040-9. doi: 10.1128/AEM.01843-13. Epub 2013 Jul 26.</citation>
    <PMID>23892749</PMID>
  </reference>
  <reference>
    <citation>Underwood MA, Kalanetra KM, Bokulich NA, Lewis ZT, Mirmiran M, Tancredi DJ, Mills DA. A comparison of two probiotic strains of bifidobacteria in premature infants. J Pediatr. 2013 Dec;163(6):1585-1591.e9. doi: 10.1016/j.jpeds.2013.07.017. Epub 2013 Aug 29.</citation>
    <PMID>23993139</PMID>
  </reference>
  <reference>
    <citation>Underwood MA, Kalanetra KM, Bokulich NA, Mirmiran M, Barile D, Tancredi DJ, German JB, Lebrilla CB, Mills DA. Prebiotic oligosaccharides in premature infants. J Pediatr Gastroenterol Nutr. 2014 Mar;58(3):352-60. doi: 10.1097/MPG.0000000000000211.</citation>
    <PMID>24135979</PMID>
  </reference>
  <reference>
    <citation>Smilowitz JT, Lebrilla CB, Mills DA, German JB, Freeman SL. Breast milk oligosaccharides: structure-function relationships in the neonate. Annu Rev Nutr. 2014;34:143-69. doi: 10.1146/annurev-nutr-071813-105721. Epub 2014 May 15. Review.</citation>
    <PMID>24850388</PMID>
  </reference>
  <reference>
    <citation>Sela DA. Bifidobacterial utilization of human milk oligosaccharides. Int J Food Microbiol. 2011 Sep 1;149(1):58-64. doi: 10.1016/j.ijfoodmicro.2011.01.025. Epub 2011 Jan 26. Review.</citation>
    <PMID>21342711</PMID>
  </reference>
  <reference>
    <citation>Sela DA, Chapman J, Adeuya A, Kim JH, Chen F, Whitehead TR, Lapidus A, Rokhsar DS, Lebrilla CB, German JB, Price NP, Richardson PM, Mills DA. The genome sequence of Bifidobacterium longum subsp. infantis reveals adaptations for milk utilization within the infant microbiome. Proc Natl Acad Sci U S A. 2008 Dec 2;105(48):18964-9. doi: 10.1073/pnas.0809584105. Epub 2008 Nov 24.</citation>
    <PMID>19033196</PMID>
  </reference>
  <reference>
    <citation>Sela DA, Garrido D, Lerno L, Wu S, Tan K, Eom HJ, Joachimiak A, Lebrilla CB, Mills DA. Bifidobacterium longum subsp. infantis ATCC 15697 α-fucosidases are active on fucosylated human milk oligosaccharides. Appl Environ Microbiol. 2012 Feb;78(3):795-803. doi: 10.1128/AEM.06762-11. Epub 2011 Dec 2.</citation>
    <PMID>22138995</PMID>
  </reference>
  <reference>
    <citation>Sela DA, Li Y, Lerno L, Wu S, Marcobal AM, German JB, Chen X, Lebrilla CB, Mills DA. An infant-associated bacterial commensal utilizes breast milk sialyloligosaccharides. J Biol Chem. 2011 Apr 8;286(14):11909-18. doi: 10.1074/jbc.M110.193359. Epub 2011 Feb 2. Erratum in: J Biol Chem. 2011 Jul 1;286(26):23620.</citation>
    <PMID>21288901</PMID>
  </reference>
  <reference>
    <citation>Sela DA, Mills DA. Nursing our microbiota: molecular linkages between bifidobacteria and milk oligosaccharides. Trends Microbiol. 2010 Jul;18(7):298-307. doi: 10.1016/j.tim.2010.03.008. Epub 2010 Apr 19. Review.</citation>
    <PMID>20409714</PMID>
  </reference>
  <reference>
    <citation>LoCascio RG, Ninonuevo MR, Freeman SL, Sela DA, Grimm R, Lebrilla CB, Mills DA, German JB. Glycoprofiling of bifidobacterial consumption of human milk oligosaccharides demonstrates strain specific, preferential consumption of small chain glycans secreted in early human lactation. J Agric Food Chem. 2007 Oct 31;55(22):8914-9. Epub 2007 Oct 5.</citation>
    <PMID>17915960</PMID>
  </reference>
  <reference>
    <citation>LoCascio RG, Desai P, Sela DA, Weimer B, Mills DA. Broad conservation of milk utilization genes in Bifidobacterium longum subsp. infantis as revealed by comparative genomic hybridization. Appl Environ Microbiol. 2010 Nov;76(22):7373-81. doi: 10.1128/AEM.00675-10. Epub 2010 Aug 27.</citation>
    <PMID>20802066</PMID>
  </reference>
  <reference>
    <citation>Dominguez-Bello MG, Costello EK, Contreras M, Magris M, Hidalgo G, Fierer N, Knight R. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proc Natl Acad Sci U S A. 2010 Jun 29;107(26):11971-5. doi: 10.1073/pnas.1002601107. Epub 2010 Jun 21.</citation>
    <PMID>20566857</PMID>
  </reference>
  <reference>
    <citation>Penders J, Gerhold K, Stobberingh EE, Thijs C, Zimmermann K, Lau S, Hamelmann E. Establishment of the intestinal microbiota and its role for atopic dermatitis in early childhood. J Allergy Clin Immunol. 2013 Sep;132(3):601-607.e8. doi: 10.1016/j.jaci.2013.05.043. Epub 2013 Jul 27.</citation>
    <PMID>23900058</PMID>
  </reference>
  <reference>
    <citation>Penders J, Thijs C, Vink C, Stelma FF, Snijders B, Kummeling I, van den Brandt PA, Stobberingh EE. Factors influencing the composition of the intestinal microbiota in early infancy. Pediatrics. 2006 Aug;118(2):511-21.</citation>
    <PMID>16882802</PMID>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2015</study_first_submitted>
  <study_first_submitted_qc>May 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2015</study_first_posted>
  <last_update_submitted>September 1, 2017</last_update_submitted>
  <last_update_submitted_qc>September 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>C-section</keyword>
  <keyword>Infants</keyword>
  <keyword>Probiotic</keyword>
  <keyword>B. infantis</keyword>
  <keyword>Microbiota</keyword>
  <keyword>Gut</keyword>
  <keyword>Breast milk</keyword>
  <keyword>Vaginal</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

